BRAINLIFE Brain Tumor Medical Database

Treatment > Irinotecan


J Neurooncol 2002 Jan;56(2):183-8. (Clinical Study)


Abstract

Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme

Chamberlain MC

University of Southern California, Norris Comprehensive Cancer Hospital, Department of Neurology, Los Angeles 90033-0804, USA. chamberl@usc.edu.

Background. A prospective Phase II study of CPT-11 in adult patients with recurrent supratentorial glioblastoma multiforme (GBM).

Methods. Forty patients (25 men, 15 women) ages 32-71 years (median 59), with recurrent GBM were treated.
All patients had previously been treated with surgery and involved field radiotherapy (median dose 60 Gy; range 59-60). Additionally, all patients were treated with adjuvant chemotherapy (BCNU in 20, PCV in 18, Procarbazine in 2).
Twenty-five patients (62%) were on anticonvulsants (phenytoin in 15, carbamazepine in 10) and 26 patients (65%) were on dexamethasone.
Recurrent disease was defined by neuroradiographic disease progression (>25% increase in tumor dimensions) using gadolinium-enhanced MR imaging.
The starting dose of CPT-11 was 400 mg/m2 followed in three weeks by 500 mg/m2, operationally defined as one cycle.
At week 6, all patients were evaluated with MRI and neurological examination.

Results. All patients were evaluable.
Two doses (one cycle) of CPT-11 were administered to all patients.
CPT-11-related toxicity included: diarrhea (16 patients, 40%); thrombocytopenia (9 patients, 23%); and neutropenia (6 patients, 15%).
No patient required transfusion nor was treatment for neutropenic fever required.
No treatment-related deaths were observed.
All patients demonstrated progressive disease following one cycle of CPT-11.

Conclusions. The lack of response to CPT-11 in this patient group with recurrent GBM suggests either CPT-11 has minimal activity or CPT-11 doses/schedule utilized in this study were sub-optimal.
The latter is supported by the modest toxicity seen in this study and the previously documented enhanced clearance of CPT-11 in patients on anticonvulsants and dexamethasone.

PMID: 11995820 [PubMed - in process]

Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11995820&dopt=Abstract


 

This website is certified by Health On the Net Foundation. Click to verify. HOMECURRENT NEURO-ONCOLOGYGLIOBLASTOMA REPORTSBRAIN TUMOR MEDICAL DATABASE SERVICES TREATMENT OPTIONS FOR GLIOBLASTOMA
DATABASE by Section: Classification | Diagnosis | Epidemiology | Etiology & Pathogenesis | Integrative Medicine | Overall Management | Prognosis | Psychosocial Aspects | Stem Cells | Treatment
DATABASE by Tumor: Glioblastoma | Medulloblastoma | Other TumorsSERVICES: About BrainLife | Children's Corner | Dedication | E-mail Alerts | Journals | Privacy Policy | Publications | Search | SiteMap
This site complies with the HONcode standard for trustworthy health information: verify here bottom